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Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarkers to predict the IFX effect for
Japanese Crohn’s disease (CD) patients by performing an association study of single nucleotide polymorphisms (SNPs) in candidate
genes in the interleukin- (IL-) 17 signaling pathway with response to IFX after 1 year of treatment.Methods. A total of 103 patients
were divided into two groups, responders and nonresponders. Twenty-eight tag SNPs in 5 genes were genotyped. The frequencies
of alleles and genotypes of each SNP were compared between responders and nonresponders in three different inheritance models.
A genetic test was performed using a combination of the associated SNPs as biomarkers. Results. Multivariate logistic regression
analysis indicated that the four variable factors, concomitant use of immunomodulators, penetrating disease, a G/G genotype of
rs766748 in IL-17F, and a C/C or C/A genotype of rs1883136 in TRAF3IP2, independently contributed to response to IFX after 1
year of treatment. Genetic test using the polymorphisms of these genes perfectly predicted the responder and nonresponder CD
patients with both concomitant use of immunomodulators and penetrating disease. Conclusion. IL17F and TRAF3IP2 are one of
IFX-related genes, useful as biomarkers of IFX response, and may be target molecules for new therapeutic drugs.
1. Introduction
Crohn’s disease (CD) is involved in idiopathic inflammatory
bowel disease (IBD) and is mainly characterized by chronic
granulomatous inflammatory changes in the gastrointestinal
tract. Although the etiology of CD is unknown, it can be
attributed to numerous environmental factors, genetic pre-
disposition, and excessive immune and inflammatory re-
sponses [1, 2]. In most cases, CD develops at a young age and
its symptoms, such as abdominal pain, diarrhea, and bloody
stool, undergo cycles of remission and relapse, eventually
resulting in the impairment of the quality of the life of CD
patients [3].
Treatments of CD are selected on the basis of the present
site of the lesions, the degree of inflammation, the presence
or absence of complications, and the previous response to
treatment. Among medical therapies, 5-amino salicylic acid
is often used for patients with mild disease severity, whereas
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steroids and/or anti-TNF-𝛼 antibodies, such as infliximab
(IFX) and adalimumab, are used for patients with moderate
or severe disease severity [4].
IFX is a chimeric anti-TNF-𝛼 monoclonal antibody that
consists of the variable region of the murine anti-TNF-𝛼
antibody and the constant region of human IgG1. IFX inhibits
the action of TNF-𝛼 by neutralizing the biological activity
of soluble TNF-𝛼, by damaging cells on membrane-bound
TNF-𝛼, and by dissociating TNF-𝛼 from its receptor [5].
IFX is widely available for the treatment of CD since 1991,
when its usefulness has been confirmed in clinical settings
worldwide. In Japan, clinical trials of IFXwere started in 1996.
In the ACCENT I randomized clinical trial carried out in
North America, Europe, and Israel, about 58% of patients
responded within 2 weeks to a single infusion of 5mg/kg
IFX. However, thereafter only 39% of these responders, who
received repeated infusions of IFX every 8 weeks, were still
in remission after 54 weeks of treatment [6]. Therefore, iden-
tification of biomarkers to predict the long-term therapeutic
effect of IFX is warranted.
Interleukin- (IL-) 17 is an inflammatory cytokine that
is secreted from Th17 cells. Within the IL-17 families, there
are six ligands (IL-17A to F) and five receptors (IL-17RA
to RE). In particular, intestinal Paneth cells express IL-17A
and colonic epithelial cells produce IL-17F [7, 8]. After IL-
17A forms a homodimerization with itself or a heterodimer-
ization with IL-17F, their complex binds to a dimerized
receptor consisting of IL-17RA and IL-17RC and subsequently
transmits signals to downstream pathways through traf3-
interacting protein 2 (TRAF3IP2), which share intracellular
signal transduction molecules, such as I-𝜅B and NF-𝜅B, with
the TNF-𝛼 signaling pathway [8–10]. Moreover, upregulation
of parallel signaling pathways, including HGF and MET, to
bypass the inhibited EGFR signaling pathway is known as
one of the resistance mechanisms to gefitinib for patients
with lung adenocarcinoma [11]. Thus, we speculate that the
same resistance mechanism may occur to the second loss
of response to IFX after 1 year of treatment. Indeed, IL-17A
is overexpressed in inflammatory lesions and in the blood
of patients with CD, multiple sclerosis, or systemic lupus
erythematosus [12–14]. Furthermore, a correlation between
the therapeutic effect of IFX and a decrease in the expression
of IL-17RA after IFX administration has been observed in
patients with rheumatoid arthritis [15]. Thus, IL-17 and its
intracellular signaling pathways play a pivotal role not only in
the pathogenesis of immune diseases including CD, but also
in the response to IFX treatment.
Here, to assess as putative genes related to response
to IFX, we examined a candidate gene-based association
study by selecting several target genes involved in the IL-17
signaling pathway and investigated whether polymorphisms
of these target genes are associated with the therapeutic effect
of IFX for Japanese CD patients. We further investigated
whether such polymorphisms could be used as new genetic
biomarkers to identify Japanese CD patients showing re-
sponse to IFX after the long-term treatment of 1 year.
2. Subjects and Methods
2.1. Subjects. The present study consisted of 113 unrelated
Japanese CD patients treated with IFX in Oita Red Cross
Hospital or Nagasaki University Hospital from 2004 to 2011.
The study protocol was approved by the Ethics Commit-
tee dealing with Human Genome and Gene Analysis at Oita
Red Cross Hospital as well as at Nagasaki University. Written
informed consent was obtained from each patient.
The diagnosis of CD was made based on the endo-
scopic, radiological, histological, and clinical criteria estab-
lished by both the World Health Organization Council for
International Organizations of Medical Sciences and the
International Organization for the Study of Inflammatory
Bowel Disease [16, 17]. Patients with indeterminate colitis,
multiple sclerosis, systemic lupus erythematosus, or any other
diagnosed autoimmune diseases were excluded from this
study.
2.2. Definition of the Therapeutic Effect of IFX. Since Crohn’s
disease activity index (CDAI) of more than 150 [18] is
regarded as active-phase CD, responders to IFX were defined
as those showing a decrease in CDAI of less than 150 and
an improvement in clinical manifestations, laboratory data,
and/or endoscopic findings. Nonresponders to IFX were
defined as those showing no change in the CDAI value or
exacerbation of disease activity.
2.3. Study Design. Of the 113 CD patients enrolled in this
study, 103 patients who had shown response to IFX after 10
weeks of IFX treatment were subjected to this association
study (Figure 1). These 103 responders to IFX at the end of
the 10-week treatment were then divided into two groups,
responders (𝑛 = 89) and nonresponders (𝑛 = 14), based
on the presence or absence of IFX effect after the long-term
IFX treatment of 1 year as shown in Figure 1. In addition,
Table 1 shows the clinical characteristics including mean age,
gender, smoking, concomitant use of immunomodulators,
colonic location, and disease behavior, of both responders
and nonresponders after 1 year of treatment (Table 1).
2.4. Selection of Tag Single Nucleotide Polymorphisms in
Candidate Genes. All candidate genes selected in this study
are involved in the IL-17 signaling pathway, including the
genes encoding interleukin-17A (IL17A/IL17A; OMIM
#603149); interleukin-17F (IL17F/IL17F; OMIM #606496);
interleukin-17 receptor A (IL17RA/IL17RA; OMIM #605461);
interleukin-17 receptor C (IL17RC/IL17RC; OMIM #610925);
and traf3-interacting protein 2 (TRAF3IP2/TRAF3IP2;
OMIM #1607043).
All of the information regarding single nucleotide poly-
morphisms (SNPs) in the candidate genes was obtained
from Japanese data in Tokyo (Rel 24/phase II Nov. 08, on
NCBI B36 assembly, dbSNP b126), which are available on the
International HapMap website [19]. Candidate tag SNPs were
selected from all SNPs in each chromosomal region including
2 kb upstream of the gene with priority for a minor allele
frequency of more than 20% in the International HapMap
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Table 1: Comparison of the clinical characteristics of responders and nonresponders to IFX after 1 year of treatment of CD patients.
Characteristics CD patients 𝑃 value
Responders Nonresponders
Number 89 14
Age, mean ± SD (years) 35.4 ± 12.9 37.8 ± 10.3 0.368
Male/female (%) 50/39 (56.2/43.8) 9/5 (64.3/35.7) 0.773
Smoking (%) 17 (19.1) 5 (35.7) 0.172
Concomitant use of immunomodulators (%) 20 (22.5) 8 (57.1) 0.007
Colonic location (%)∗
Ilium 16 (18.0) 2 (14.3) 1.000
Colon 17 (19.1) 3 (21.4) 1.000
Ileocolon 56 (62.9) 9 (64.3) 1.000
Disease behavior (%)∗
Nonstricturing/penetrating 43 (48.3) 5 (35.7) 0.409
Stricturing 37 (41.6) 3 (21.4) 0.238
Penetrating 18 (20.2) 8 (57.1) 0.006
∗Classification according to Montreal Classification for CD.












Evaluation of clinical and genetic factors 
Figure 1: Flowchart of study design. A total of 113 CD patients were
enrolled in this study.Of these patients, at the end of the 10-week IFX
treatment, 103 patients showed response to IFX, 8 patients indicated
loss of response to IFX, and IFX treatments of 2 patients were
stopped due to side reactions of IFX. After 1 year of IFX treatment,
89 of the 103 patients still showed response to IFX, but the other 14
patients showed loss of response to IFX. CD: Crohn’s disease; IFX:
infliximab.
data. Subsequently, genotyped tag SNPs among the candidate
tag SNPs were determined based on linkage disequilibrium
(LD) tagging using the Haploview 4.1 software program (𝑟2 >
0.8) [20].
Twenty-eight tag SNPs, five in IL17A, seven in IL17F,
eight in IL17RA, two in IL17RC, and six in TRAF3IP2, were
selected as the genotyped tag SNPs. Information regarding
the structure of the gene and the positions of the genotyped
tag SNP sites in each candidate gene is shown in Figure 2.
2.5. Genotyping of Tag SNPs in Each Gene. Genomic DNA
was extracted from whole blood samples using a DNA
Extractor WB-Rapid Kit (Wako, Osaka, Japan) or a Quick
Gene DNA Whole Blood Kit S (Fujifilm, Tokyo, Japan) with
a Quick Gene-800 (Fujifilm) according to the manufacturer’s
protocol.
A total of 28 tag SNPs in 5 candidate genes were gen-
otyped by polymerase chain reaction- (PCR-) restriction
fragment length polymorphism (RFLP) or PCR-direct DNA
sequencing method (Table 2) [21]. The polymorphic region
was amplified by PCR with a GeneAmp PCR System 9700
thermal cycler (Life Technologies, Carlsbad, CA, USA) using
20 ng genomic DNA in a 25 𝜇L reaction mixture containing
1x GoTaq Green master mix (Promega, Madison, WI, USA)
and 15 pmol each of forward and reverse primers (Table 2).
The amplification protocol consisted of initial denaturation
at 95∘C for 2 minutes, followed by 30 or 35 cycles of
denaturation at 95∘C for 30 seconds, annealing for 30 seconds
at the appropriate temperature for the primer pair (Table 2),
extension at 72∘C for 30 seconds, and final extension at 72∘C
for 5 minutes.
For the RFLP method, the PCR products were digested
with the relevant restriction enzyme (Table 2), separated by
electrophoresis on a 6% to 12% polyacrylamide gel (Nacalai
Tesque, Kyoto, Japan) or a 2% ME-agarose gel (Nacalai
Tesque), stainedwith ethidiumbromide, and visualized using
an ultraviolet transilluminator (Alpha Innotech Co., San
Leandro, CA, USA).
For the direct DNA sequencing method, the PCR prod-
ucts were treated with ExoSAP-IT (Amersham Pharmacia
Biotech, Piscataway, NJ, USA) and cycle sequenced using a
BigDye Terminator v3.1 Cycle Sequencing FS Ready Reaction
Kit (Life Technologies).The cycle sequencing was hot-started
at 96∘C for 30 seconds, followed by 25 cycles of denaturation
at 96∘C for 10 seconds, annealing at 50∘C for 5 seconds, and
extension at 60∘C for 4 minutes using 1 pmol PCR forward or
reverse primer. After the sequencing reaction solutions were
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Figure 2: Gene structures and locations of genotyped tag SNP sites in each gene. The horizontal bars indicate the genomic sequences of
candidate genes. Full boxes represent exons in each gene, and open boxes show the untranslated regions. The arrows indicate the positions
of the genotyped tag SNP sites in this study and their names are presented above each site. SNPs: single nucleotide polymorphisms; CDS:
coding sequence; UTR: untranslated region.
purified using SephadexG-50 superfine columns (Amersham
Pharmacia Biotech), the samples were dried and sequenced
with an ABI Prism 3100 Genetic Analyzer (Life Technolo-
gies).
2.6. Statistical Analyses. The mean age of IFX-responder
CD patients and nonresponder CD patients after 1 year of
treatment was presented as means ± standard deviation and
was compared using the Mann-Whitney 𝑈 test. The other
clinical characteristics were compared using a chi-square
or Fisher’s exact test. The above statistical analyses were
performed using the IBM SPSS Statistics 20 software package
(IBM Japan, Tokyo, Japan) or Prism 6 (GraphPad Software,
Inc., La Jolla, CA, USA).
The significance of deviation from the Hardy-Weinberg
equilibrium (HWE) and LD between pairs of SNPs was
analyzed using a chi-square test based on the expectation-
maximization algorithm using the SNPAlyze 7.0 standard
software package (Dynacom Inc., Chiba, Japan). The fre-
quencies of alleles and genotypes were compared between
responders and nonresponders after 1 year of treatment using
the chi-squared or Fisher’s exact test with odds ratio (OR)
and 95% confidence interval in three different inheritance
models: the allele, the minor allele dominant, and the minor
allele recessive, using the SNPAlyze 7.0 standard software
package.
In addition to univariate analyses, multivariate logistic
regression analysis was carried out for analysis of the inter-
action of clinical environmental factors and putative genetic
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factors with the therapeutic effect of IFX after 1 year of
treatment using JMP Pro 11 (SAS Institute Inc., Tokyo, Japan).
A 𝑃 value of less than 0.05 was considered to be statistically
significant.
3. Results
3.1. Comparison of the Clinical Characteristics of Responders
and Nonresponders to IFX. When the clinical characteristics
of responders and nonresponders to IFX after 1 year of
treatment were compared, there were significant differences
in the concomitant use of immunomodulators as well as in
the presence of penetrating disease behavior between the
two groups (Table 1). Thus, the percentage of nonresponder
CD patients concomitantly treated with immunomodulators
was higher than that of the responders (57.1% versus 22.5%,
𝑃 = 0.007). The percentage of nonresponder CD patients
with penetrating disease was also higher than that of the
responders (57.1% versus 20.2%, 𝑃 = 0.006).
3.2. Association between Tag SNPs and Response to IFX after 1
Year of Treatment. Comparison of the distribution of alleles
and genotypes of tag SNPs in each gene between responders
and nonresponders to IFX after 1 year of treatment is shown
in Table 3. The three tag SNPs, rs5748863 in IL17RA and
rs10872070 and rs2075966 in TRAF3IP2, were excluded from
the subsequent analyses because they were not in HWE.
Chi-square or Fisher’s exact test in three different inheri-
tance models indicated that the frequency of a heterozygous
G/A genotype or a minor homozygous A/A genotype of
rs766748 in IL17F in the minor allele dominant model was
significantly decreased in responders as compared to that
in nonresponders (𝑃 = 0.019, OR = 0.203; Table 3). This
result implies that there was a ∼4.9-fold loss of response
to IFX in the nonresponders with these genotypes after 1
year of treatment as compared to the responders. Conversely,
possessing a major homozygous G/G genotype of rs766748
in IL17F indicated that there was a ∼4.9-fold response to
IFX in the responders with this genotype as compared to the
nonresponders.
Moreover, the frequency of a minor homozygous A/A
genotype of rs1883136 in TRAF3IP2 in the minor allele
recessive model was significantly lower in responders in
comparison to that in nonresponders (𝑃 = 0.041, OR =
0.213; Table 3), indicating that this genotype is associatedwith
a ∼4.7-fold loss of response to IFX. Conversely, possessing
a major homozygous C/C genotype or a heterozygous C/A
genotype of rs1883136 in TRAF3IP2 indicated a ∼4.7-fold
increase in response to IFX after 1 year of treatment.
3.3. The Interaction of Genetic and Environmental Factors on
Response to IFX after 1 Year of Treatment. Univariate analyses
of the differences between responders and nonresponders
indicated that the environmental factors of nonconcomitant
use of immunomodulators or nonpenetrating disease and the
genetic factors of the G/G genotype of rs766748 in IL17F or
the C/C or C/A genotype of rs1883136 in TRAF3IP2 showed
response to IFX after 1 year of treatment. We then performed
multivariate logistic regression analysis of the influence of the
interaction of these factors on response to IFX after 1 year
of treatment. This analysis revealed that these four variable
factors independently contributed to response to IFX (𝑃 =
0.0162, OR = 5.281, 𝑃 = 0.0073, OR = 6.529, 𝑃 = 0.0213,
OR = 5.123, and 𝑃 = 0.0149, OR = 10.43, resp.; Table 4).
3.4. Verification of Genetic Test for Prediction of Response to
IFX. In order to better predict the response to IFX for CD
patients after 1 year of treatment, we carried out a genetic
test using a combination of the two independent genetic
factors (IL17F and TRAF3IP2 genotypes) with or without the
concomitant use of immunomodulators and/or penetrating
disease (Tables 5 and 6). With regard to the patients con-
comitantly treated with immunomodulators, the prediction
panel indicated that both the G/G genotype of rs766748 in
IL17F and theC/C orC/A genotype of rs1883136 inTRAF3IP2
were strongly associated with response to IFX in the CD
patients with use of immunomodulators (𝑃 = 0.0019, OR =
37.92; Table 5). In this genetic test, the sensitivity, specificity,
positive predictive value, and negative predictive value were
estimated at 70.0%, 100%, 100%, and 57.1%, respectively.
Moreover, when the CD patients with both the concomi-
tant use of immunomodulators and penetrating disease were
considered, the above described polymorphisms showed a
close association with response to IFX with the sensitivity,
specificity, positive predictive value, and negative predictive
value all estimated as 100% (Table 6).
On the other hand, there were no significant associations
with response to IFX after 1 year of treatment in the patients
with other combinations of with or without the concomitant
use of immunomodulators and/or penetrating disease (Sup-
plemental Tables 1–6 in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/416838).
4. Discussion
The present study is the first report to show that each of the
genetic factors, polymorphisms of IL-17F andTRAF3IP2, and
the clinical risk factors, concomitant use of immunomod-
ulators and penetrating disease, independently contributed
to the therapeutic effect of IFX after the long-term (1 year)
IFX treatment of Japanese CD patients. The CD patients
possessing the G/G genotype of rs766748 in IL-17F or the
C/C or C/A genotype of rs1883136 in TRAF3IP2, or having
nonuse of immunomodulators or nonpenetrating disease
behavior, showed good response to IFX after 1 year of
treatment. Conversely, the patients possessing the G/A or
A/A genotype of rs766748 in IL-17F or the A/A genotype
of rs1883136 in TRAF3IP2, or having the concomitant use
of immunomodulators or penetrating disease behavior, dis-
played the secondary loss of response to IFX after 1 year of
treatment although they had presented good response to IFX
at the end of the 10-week IFX treatment.
TRAF3IP2 is an IL-17R adaptor protein that is also
referred to as NF-𝜅B activator 1. After a heterodimer of IL-
17A and IL-17F binds to their receptor, that is, comprised of
IL-17RA and IL-17RC, the IL17-IL17R complex signals induce
BioMed Research International 7
Table 3: Allele and genotype comparisons in three inheritancemodels between responders and nonresponders to IFX after 1 year of treatment
of CD patients.
Gene symbol Tag SNP(Major >minor) Genotype
Number of genotypes (%)
Inheritance model∗ 𝑃 value OR 95% CIResponders Nonresponders




MAF 0.337 0.321 Allele 0.870 1.073 0.458–2.517
A/A 39 (43.8) 6 (42.9)
A/G 40 (44.9) 7 (50.0) Dominant 0.946 0.962 0.308–3.002
G/G 10 (11.2) 1 (7.1) Recessive 1.000 1.646 0.194–13.96
rs8193036
C > T
MAF 0.438 0.393 Allele 0.653 1.205 0.534–2.722
C/C 32 (36.0) 5 (35.7)
C/T 36 (40.4) 7 (50.0) Dominant 1.000 0.990 0.305–3.208
T/T 21 (23.6) 2 (14.3) Recessive 0.730 1.853 0.384–8.954
rs3819024
G > A
MAF 0.421 0.423 Allele 0.669 0.840 0.377–1.870
G/G 33 (37.1) 5 (35.7)
G/A 37 (41.6) 5 (35.7) Dominant 1.000 0.943 0.291–3.053
A/A 19 (21.3) 4 (28.6) Recessive 0.509 0.679 0.191–2.406
rs2275913
G > A
MAF 0.343 0.393 Allele 0.605 0.806 0.355–1.828
G/G 40 (44.9) 5 (35.7)
G/A 37 (41.6) 7 (50.0) Dominant 0.575 0.681 0.211–2.194
A/A 12 (13.5) 2 (14.3) Recessive 1.000 0.935 0.186–4.707
rs3819025
G > A
MAF 0.292 0.321 Allele 0.752 0.871 0.370–2.052
G/G 47 (52.8) 7 (50.0)
G/A 32 (36.0) 5 (35.7) Dominant 0.845 0.894 0.289–2.760




MAF 0.157 0.071 Allele 0.385 2.427 0.545–10.81
T/T 63 (70.8) 12 (85.7)
T/C 24 (27.0) 2 (14.3) Dominant 0.341 2.476 0.518–11.85
C/C 2 (2.2) 0 (0) Recessive 1.000 0.829 0.038–18.17
rs766748
G > A
MAF 0.247 0.429 Allele 0.045 0.438 0.192–0.997
G/G 51 (57.3) 3 (21.4)
G/A 32 (36.0) 10 (71.4) Dominant 0.019 0.203 0.053–0.779
A/A 6 (6.7) 1 (7.1) Recessive 1.000 0.940 0.105–8.454
rs12201582
C > A
MAF 0.112 0.143 Allele 0.750 0.760 0.239–2.414
C/C 70 (78.7) 10 (71.4)
C/A 18 (20.2) 4 (28.6) Dominant 0.509 0.679 0.191–2.406
A/A 1 (1.1) 0 (0) Recessive 1.000 0.554 0.021–14.29
rs9382084
T > G
MAF 0.433 0.357 Allele 0.453 1.372 0.600–3.141
T/T 34 (38.2) 4 (28.6)
T/G 33 (37.1) 10 (71.4) Dominant 0.564 0.647 0.188–2.227
G/G 22 (24.7) 0 (0) Recessive 0.037 9.671 0.554–168.8
rs722323
C > T
MAF 0.438 0.429 Allele 0.924 1.040 0.465–2.326
C/C 31 (34.8) 4 (28.6)
C/T 38 (42.7) 8 (57.1) Dominant 0.768 0.748 0.217–2.584
T/T 20 (22.5) 2 (14.3) Recessive 0.729 1.739 0.359–8.425
rs1266828
T > C
MAF 0.146 0.143 Allele 1.000 1.026 0.329–3.201
T/T 66 (74.2) 10 (71.4)
T/C 20 (22.5) 4 (28.6) Dominant 0.757 0.871 0.249–3.051
C/C 3 (3.4) 0 (0) Recessive 1.000 1.173 0.058–23.94
rs2294834
A > C
MAF 0.157 0.179 Allele 0.783 0.859 0.301–2.449
A/A 65 (73.0) 9 (64.3)
A/C 20 (22.5) 5 (35.7) Dominant 0.530 0.665 0.202–2.184
C/C 4 (4.5) 0 (0) Recessive 1.000 1.526 0.078–29.90
8 BioMed Research International
Table 3: Continued.
Gene symbol Tag SNP(Major >minor) Genotype
Number of genotypes (%)
Inheritance model∗ 𝑃 value OR 95% CIResponders Nonresponders




MAF 0.365 0.429 Allele 0.519 0.767 0.342–1.721
T/T 34 (38.2) 5 (35.7)
T/G 45 (50.6) 6 (42.9) Dominant 1.000 0.899 0.278–2.908
G/G 10 (11.2) 3 (21.4) Recessive 0.379 0.464 0.110–1.952
rs2241042
A > C
MAF 0.225 0.286 Allele 0.478 0.725 0.297–1.769
A/A 52 (58.4) 6 (42.9)
A/C 34 (38.2) 8 (57.1) Dominant 0.275 0.534 0.171–1.668
C/C 3 (3.4) 0 (0) Recessive 1.000 1.173 0.058–23.94
rs5748864
G > A
MAF 0.478 0.536 Allele 0.567 0.792 0.356–1.761
G/G 24 (27.0) 3 (21.4)
G/A 45 (50.6) 7 (50.0) Dominant 0.757 0.739 0.190–2.878
A/A 20 (22.5) 4 (28.6) Recessive 0.734 0.725 0.205–2.560
rs2241044
A > C
MAF 0.292 0.357 Allele 0.486 0.743 0.321–1.717
A/A 43 (48.3) 5 (35.7)
A/C 40 (44.9) 8 (57.1) Dominant 0.407 0.594 0.185–1.915
C/C 6 (6.7) 1 (7.1) Recessive 1.000 0.940 0.105–8.454
rs2241049
A > G
MAF 0.326 0.429 Allele 0.286 0.644 0.286–1.451
A/A 43 (48.3) 6 (42.9)
A/G 34 (38.2) 4 (28.6) Dominant 0.704 0.802 0.257–2.502
G/G 12 (13.5) 4 (28.6) Recessive 0.225 0.390 0.105–1.444
rs2229151
G > A
MAF 0.287 0.321 Allele 0.706 0.849 0.360–1.998
G/G 44 (49.4) 7 (50.0)
G/A 39 (43.8) 5 (35.7) Dominant 0.969 1.023 0.331–3.158
A/A 6 (6.7) 2 (14.3) Recessive 0.297 0.434 0.078–2.401
rs2895332
A > G
MAF 0.348 0.286 Allele 0.517 1.336 0.556–3.209
A/A 37 (41.6) 6 (42.9)
A/G 42 (47.2) 8 (57.1) Dominant 0.928 1.054 0.337–3.295




MAF 0.112 0 Allele 0.082 7.372 0.433–125.5
G/G 71 (79.8) 14 (100)
G/A 16 (18.0) 0 (0) Dominant 0.122 7.503 0.427–131.8
A/A 2 (2.2) 0 (0) Recessive 1.000 0.829 0.038–18.17
rs279545
A > G
MAF 0.213 0.179 Allele 0.806 1.249 0.445–3.503
A/A 55 (61.8) 9 (64.3)
A/G 30 (33.7) 5 (35.7) Dominant 1.000 1.113 0.344–3.600




MAF 0.365 0.500 Allele 0.173 0.575 0.258–1.282
T/T 35 (39.3) 4 (28.6)
T/C 43 (48.3) 6 (42.9) Dominant 0.560 0.617 0.179–2.123
C/C 11 (12.4) 4 (28.6) Recessive 0.120 0.353 0.094–1.321
rs1883136
C > A
MAF 0.292 0.464 Allele 0.068 0.476 0.212–1.071
C/C 44 (49.4) 5 (35.7)
C/A 38 (42.7) 5 (35.7) Dominant 0.398 0.568 0.176–1.830
A/A 7 (7.9) 4 (28.6) Recessive 0.041 0.213 0.053–0.860
rs1040383
C > G
MAF 0.528 0.357 Allele 0.257 1.609 0.703–3.679
C/C 24 (27.0) 6 (42.9)
C/G 46 (51.7) 6 (42.9) Dominant 0.224 2.031 0.638–6.465
G/G 19 (21.3) 2 (14.3) Recessive 0.729 1.629 0.335–7.914
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Table 3: Continued.
Gene symbol Tag SNP(Major >minor) Genotype
Number of genotypes (%)
Inheritance model∗ 𝑃 value OR 95% CIResponders Nonresponders
𝑛 = 89 𝑛 = 14
rs9374263
G > C
MAF 0.331 0.429 Allele 0.315 0.661 0.294–1.488
G/G 40 (44.9) 6 (42.9)
G/C 39 (43.8) 4 (28.6) Dominant 0.884 0.919 0.294–2.868
C/C 10 (11.2) 4 (28.6) Recessive 0.096 0.317 0.083–1.201
∗Allele: allele model; Dominant: the minor allele dominant model; Recessive: the minor allele recessive model.
IFX: infliximab; CD: Crohn’s disease; SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odds ratio; CI: confidence interval.
Table 4: The interaction of genetic and environmental factors for response to IFX after 1 year of treatment of CD patients.
Factor OR (95% CI) 𝑃 value∗
Nonconcomitant use of immunomodulators 5.281 (1.360–23.09) 0.0162
Nonpenetrating 6.529 (1.651–30.41) 0.0073
G/G genotype of rs766748 in IL17F 5.123 (1.261–27.77) 0.0213
C/C or C/A genotype of rs1883136 in TRAF3IP2 10.43 (1.603–77.68) 0.0149
∗Factors were statistically analyzed by multivariate logistic regression analysis.
IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval.
Table 5: Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with concomitant use of immunomo-
dulators.
Factor
Number of CD patients (%)
OR (95% CI) 𝑃 value∗Responders Nonresponders
𝑛 = 20 𝑛 = 8
Both G/G genotype of rs766748 in IL17F and C/C
and C/A genotype of rs1883136 in TRAF3IP2 14 (70.0) 0 (0) 37.92 (1.890–761.1) 0.0019
Others 6 (30.0) 8 (100)
∗Factors were statistically analyzed by Fisher’s exact test.
IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval.
the activation of TRAF3IP2 and TNF receptor-associated
factor 6. This signaling pathway eventually leads to the
production of proinflammatory cytokines through NF-𝜅B
[8–10, 22–24]. Moreover, TRAF3IP2 interacts with other
TRAF proteins such as TRAF3 and TRAF6 that play multiple
signaling roles in the IL-17 and TNF-𝛼 signaling pathways
[8, 22, 25, 26]. For these reasons, it seems reasonable to
speculate that the polymorphisms in IL-17F and TRAF3IP2
identified in this study may affect these signaling pathways.
Although we did not functionally analyze these SNPs, it is
possible that in the intestines of nonresponder CD patients
with genetic backgrounds of the G/A or A/A genotype of
rs766748 in IL-17F or of the A/A genotype of rs1883136 in
TRAF3IP2 may affect the slight gain-of-function of both IL-
17F and TRAF3IP2, thereby leading to a certain level of
activation of both the IL-17 and TNF-𝛼 signaling pathways. It
is known that (1) downstream signal transduction molecules,
including I-𝜅B and NF-𝜅B, are shared by the IL-17 and
TNF-𝛼 signaling pathways [8–10], (2) IL-17R knock-out mice
are protected from inflammatory diseases including CD
[27], and (3) TRAF3IP2-deficient mice are protected against
dextran sodium sulfate-induced colitis, which presents with
IBD-like manifestations [28]. Thus, elevated production of
proinflammatory cytokines through the activation of both the
IL-17 and TNF-𝛼 signaling pathways, whichmay occur in the
IFX nonresponders, can lead to perpetuation of the chronic
intestinal inflammatory process and might thereby result in
the secondary loss of response to IFX after 1 year of treatment.
Since these patients showed good response to IFX at the
end of the 10-week treatment, IFX treatment can inhibit the
weak activation of the IL-17 and TNF-𝛼 signaling pathways
that might occur due to these polymorphisms of IL-17F and
TRAF3IP2 until the 10-week IFX treatment of these patients.
However, the secondary loss of response to IFX, which occurs
in these CD patients in the period from the end of the 10
weeks to the end of the 1 year of IFX treatment, may be due to
a number of factors.Thus, during this period, the diminution
of IFX-induced inhibition due to other environmental and
genetic factors may lead to activation of the IL-17 and TNF-
𝛼 signaling pathways, thereby resulting in the secondary loss
of response to IFX. For example, various clinical risk factors,
including smoking, enhancement of IFX clearance, new
production of anti-IFX antibodies, a decrease in the blood
concentration of IFX, and other unknown environmental
factors and host genetic variations, can also contribute to
the secondary loss of response to IFX [29–35]. In this study,
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Table 6: Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with both concomitant use of
immunomodulators and penetrating disease.
Factor
Number of CD patients (%)
OR (95% CI) 𝑃 value∗Responders Nonresponders
𝑛 = 4 𝑛 = 5
Both G/G genotype of rs766748 in IL17F and C/C
and C/A genotype of rs1883136 in TRAF3IP2 4 (100) 0 (0) 99.00 (1.618–6059) 0.0079
Others 0 (0) 5 (100)
∗Factors were statistically analyzed by Fisher’s exact test.
IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval.
among the clinical factors such as smoking, concomitant
use of immunomodulators, colonic location, and disease
behavior thatwe analyzed, two factors, the concomitant use of
immunomodulators and penetrating disease, independently
contributed to response to IFX after 1 year of treatment of the
CD patient population.
With regard to this association, even if the effect of IL-
17F is weaker than that of IL-17A, the polymorphisms of IL-
17F were associated with the therapeutic effect of IFX after 1
year of treatment, but not IL-17A. Although we did not carry
out protein analysis of IL-17, we guess the possibilities that (1)
the percentage of homodimerization of IL-17F protein may
be higher in the responder CD patients, but lower in the
nonresponders, (2) the level of the gain-of-function of the
IL-17 signaling pathway due to the G/A or A/A genotype of
rs766748 in IL-17Fmay be accelerated in comparison to other
polymorphisms of IL-17F, and (3) the activation of the IL-17
signaling pathwaymay be independent of the polymorphisms
of IL-17A. Additional studies are needed to elucidate this
mechanism.
On the other hand, the production of proinflammatory
cytokines through the IL-17 and TNF-𝛼 signaling pathways
may be downregulated in the CD patients possessing the
G/G genotype of rs766748 in IL-17F and/or the C/C or C/A
genotype of rs1883136 in TRAF3IP2. Therefore, IFX-induced
inhibition of the TNF-𝛼 signals may keep stronger effect on
IFX response than various risk factors, thereby resulting in
a good response to IFX after 1 year of treatment of these
patients.
With regard to other host genetic variations, the pre-
viously reported association studies of rheumatoid arthritis
(RA) have shown that some SNPs in genes encoding proteins,
such as p38 mitogen-activated protein kinase, AF4/FMR2
family, member 3, CD226, protein tyrosine phosphatase
receptor type C, Fc gamma receptors IIA and IIIA, and
tumor necrosis factor receptor superfamily member 1B, are
associated with response to anti-TNF treatment [36–40]. It
has been suggested that these SNPs are also involved in the
therapeutic effect of IFX in CD patients. It is necessary to
confirm that these RA-responsible SNPs do contribute to the
effect of IFX in CD patients.
From the perspective of using genetic biomarkers to
predict response to IFX for CD patients after 1 year of
treatment, the present genetic test using the associated SNPs
as biomarkers for the CD patients with the concomitant
use of immunomodulators showed the highest specificity as
well as the positive predictive value of 100% with significant
differences. In addition, when this test was limited to the CD
patients with both concomitant use of immunomodulators
and penetrating disease, each of the sensitivity, specificity,
positive predictive value, and negative predictive value was
100% with significant differences. These data suggest that,
even though the CD patients possessing these polymor-
phisms of IL-17F and TRAF3IP2 have clinical risk factors
including the concomitant use of immunomodulators and
penetrating disease, they should be treated with IFX because
of the 100% sensitivity and 100% positive predictive value of
the test. Conversely, the patients not possessing these poly-
morphisms of IL-17F and TRAF3IP2 should not be treated
with IFX based on the 100% test value for the specificity and
negative predictive value.Therefore, the CD patients possess-
ing these polymorphisms of IL-17F and TRAF3IP2 together
with both the concomitant use of immunomodulators and
penetrating disease can perfectly indicate the responders and
nonresponders to IFX after 1 year of IFX treatment.
5. Conclusion
This is the first report that IL-17F and TRAF3IP2 are IFX-
related genes in Japanese CD patients. The combination
of the polymorphisms in these two genes is useful as a
new biomarker to predict response to IFX after 1 year of
treatment. Since the activation of the IL-17 signaling pathway
may be associated with the secondary loss of response to
IFX, the signal transduction molecules including IL-17F and
TRAF3IP2 in the IL-17 signaling pathway might be possible
new therapeutic targets for a part of CD and/or therapeutic
agents to overcome the secondary loss of response to IFX
treatment.
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